CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,619
- in 1 filing, $6K under 10b5-1 plans
Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion | +2,650 | $0.30 | $795 | 88,350 |
| 2022-03-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,062 | $52.43 | $56K | 87,288 |
| 2022-03-11 | Lachey Jennifer Chief Scientific Officer | Sale | −713 | $53.36 | $38K | 86,575 |
| 2022-03-11 | Lachey Jennifer Chief Scientific Officer | Sale | −875 | $54.54 | $48K | 85,700 |
| 2022-03-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,650 | 84,655 | ||
| 2022-02-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion | +2,650 | $0.30 | $795 | 88,350 |
| 2022-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,073 | $51.50 | $55K | 87,277 |
| 2022-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,378 | $52.35 | $72K | 85,899 |
| 2022-02-11 | Lachey Jennifer Chief Scientific Officer | Sale | −199 | $53.10 | $11K | 85,700 |
| 2022-02-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,650 | 87,305 | ||
| 2022-02-01 | Rovaldi Christopher Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2022-01-21 | Seehra Jasbir Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +165,000 | 165,000 | ||
| 2022-01-21 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-01-21 | Lachey Jennifer Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-01-21 | Cooper Simon Peter Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-01-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion | +2,650 | $0.30 | $795 | 88,350 |
| 2022-01-11 | Lachey Jennifer Chief Scientific Officer | Sale | −320 | $52.01 | $17K | 88,030 |
| 2022-01-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,196 | $53.56 | $64K | 86,834 |
| 2022-01-11 | Lachey Jennifer Chief Scientific Officer | Sale | −1,134 | $54.45 | $62K | 85,700 |
| 2022-01-11 | Lachey Jennifer Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,650 | 89,955 |
Page 11 of 36 · 707 trades